CA
ESPR

Cliff Asness’s Esperion Therapeutics ESPR Stock Holding History

Cliff Asness’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-314,866
Closed -$863K – 3919
2026
Q1 		$863K Buy
314,866
+24,352
+8% +$77.1K ﹤0.01% 2852
2025
Q4 		$1.07M Buy
290,514
+5,608
+2% +$18.1K ﹤0.01% 2504
2025
Q3 		$755K Buy
284,906
+100,539
+55% +$194K ﹤0.01% 2593
2025
Q2 		$181K Buy
184,367
+122,480
+198% +$123K ﹤0.01% 3072
2025
Q1 		$89.1K Sell
61,887
-136,032
-69% -$251K ﹤0.01% 3029
2024
Q4 		$435K Sell
197,919
-31,411
-14% -$73.3K ﹤0.01% 2312
2024
Q3 		$378K Buy
+229,330
New +$463K ﹤0.01% 2288
2023
Q4 		– Sell
-202,985
Closed -$199K – 2363
2023
Q3 		$199K Buy
+202,985
New +$294K ﹤0.01% 2145
2022
Q2 		– Sell
-41,059
Closed -$191K – 2210
2022
Q1 		$191K Buy
+41,059
New +$176K ﹤0.01% 2072
2020
Q2 		– Sell
-10,774
Closed -$340K – 2117
2020
Q1 		$340K Buy
+10,774
New +$569K ﹤0.01% 1726
2019
Q4 		– Sell
-6,216
Closed -$228K – 2135
2019
Q3 		$228K Buy
+6,216
New +$246K ﹤0.01% 1978
2018
Q3 		– Sell
-11,442
Closed -$448K – 2281
2018
Q2 		$448K Sell
11,442
-51,894
-82% -$2.62M ﹤0.01% 2013
2018
Q1 		$4.58M Buy
63,336
+37,956
+150% +$2.79M ﹤0.01% 1035
2017
Q4 		$1.67M Sell
25,380
-78,346
-76% -$4.22M ﹤0.01% 1452
2017
Q3 		$5.2M Buy
103,726
+74,319
+253% +$3.58M 0.01% 1005
2017
Q2 		$1.36M Buy
+29,407
New +$1.08M ﹤0.01% 1552
2015
Q4 		– Sell
-60,167
Closed -$1.42M – 2254
2015
Q3 		$1.42M Sell
60,167
-16,129
-21% -$1.01M ﹤0.01% 1276
2015
Q2 		$6.24M Buy
76,296
+8,296
+12% +$812K 0.01% 753
2015
Q1 		$6.3M Buy
68,000
+55,900
+462% +$3.61M 0.01% 701
2014
Q4 		$489K Buy
+12,100
New +$370K ﹤0.01% 1975

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Cliff Asness's ESPR Position: Q2 2026 in Review

Cliff Asness sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 314,866 shares — an estimated $863K sold.

Cliff Asness first reported a position in ESPR in Q4 2014 and held it in 20 quarters. The position peaked at $6.3M in Q1 2015. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Cliff Asness reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cliff Asness sold 314,866 Esperion Therapeutics shares in Q2 2026, an estimated $863K.
  • Cliff Asness first reported a position in Esperion Therapeutics in Q4 2014 and held it in 20 quarters.
  • Cliff Asness's Esperion Therapeutics position peaked at $6.3M in Q1 2015.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.